VERU (Veru Inc) Cumulative Company Assets

Official company branding of Veru Inc (VERU)

The historical price action of Veru Inc. (VERU) total assets on GURU.Markets is 32.18. Veru Inc. (VERU) generates revenue through the sale of feminine hygiene products and the development of prostate and breast cancer treatments. Shifts in therapy vectors and bureaucratic complexities have created earnings volatility. To accelerate drug releases, the business is implementing software robots and automated molecule analysis stations.

Veru Inc (VERU) Aggregate Company Assets: for the period 07/04/2022 - 10/29/2026

Financial and market metric breakdowns for Veru Pharma (VERU)

- market value and analyst target forecast:
Stock Price verupharma.com|VERU - Analyst Consensus Forecast
- business market valuation indicators:
Market Valuation Veru Corporation|VERU - Enterprise Value
- company book value details:
Book Value per Share Veru|VERU - Company Book Value|Capitalization to Book Value Ratio verupharma.com|VERU - Company Total Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Veru Inc.|VERU - Long-Term Debt to Capital|Current Liabilities to Capital Veru Corporation|VERU - Company Debts|Debt to Net Assets Ratio Veru Corporation|VERU - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Veru|Quick Liquidity Indicator verupharma.com
- earnings and market multiples details:
VERU - Net Income
Basic company analysis:verupharma.com (VERU)
Core merchandise of Veru

The asset dynamics of Veru Inc. (VERU) reflect the scale of business transformation as the company shifts from the sexual health segment to the promotion of oncology drugs. An analysis of controlled resources, calculated reversely via ROA, allows for the filtering of market noise and the assessment of the real value of assets and liabilities, which is critical for determining capital stability during the rebalancing of the company's revenue structure.

Key competitors

beigene.com (ONC) - Company Total Assets|HALO (Halozyme) - Company Total Assets|Cumulative Company Assets Revolution Medicines Inc (RVMD)|Company Total Assets AAPG|Company Total Assets CG Oncology Therapeutics (CGON)|Aggregate Company Assets UroGen Pharma Ltd. URGN|BCAX: Total Business Assets|Personalis - Company Total Assets|Erasca Inc (ERAS) - Cumulative Company Assets|DCTH: Company Total Assets|Company Assets Y-mAbs Corp (YMAB)|Aggregate Company Assets Aura Biosciences, Inc.|CADL: Aggregate Asset Value|Cumulative Company Assets ARAY (Accuray)|SLS (sellaslifesciences.com) - Aggregate Asset Value|Company Total Assets ACTU (Actuate Therapeutics, Inc)|CTOR - Cumulative Company Assets|HURA: Cumulative Company Assets|TARA - Company Total Assets|Fate Therapeutics (FATE) - Aggregate Company Assets|Aadi Bioscience - Aggregate Asset Value|TCRX (TScan Therapeutics Inc) - Company Total Assets|Company Assets Champions Oncology Corp CSBR|Cumulative Company Assets XBIT (XBiotech Inc.)|Aggregate Company Assets CVM (cel-sci.com)|Company Total Assets OSTX (OS Therapies)|radiopharmtheranostics.com (RADX) - Company Assets|ARTV - Aggregate Company Assets|Aggregate Asset Value ANL (Adlai Nortye Ltd.)|TPST (Tempest Therapeutics) - Cumulative Company Assets|Xilio Therapeutics (XLO) - Company Total Assets|Cumulative Company Assets RENB|MURA: Aggregate Asset Value|Company Total Assets KAPA|Company Total Asset Base onkuretherapeutics.com|Aggregate Company Assets CytoMed Therapeutics Limited GDTC|CRIS: Total Business Assets|Apollomics Corp - Company Total Assets|Tharimmune Inc (THAR) - Cumulative Company Assets|ADVB (advanbiomed.com) - Cumulative Company Assets|GNPX - Company Total Asset Base|Cumulative Company Assets CLDI|Aggregate Company Assets SBFM|Company Total Assets XBIO|SLRX - Company Assets|Aggregate Company Assets Purple Biotech Corp PPBT|Aggregate Asset Value AONC|BGNE: Cumulative Company Assets|CKPT - Company Total Assets|ELEV: Company Total Assets|Cumulative Company Assets iCAD|IKNA (Ikena Oncology Inc.) - Company Total Assets|Company Total Assets Notable Labs Corp|Aggregate Company Assets Viracta Therapeutics (VIRX)|morphosys.com - Total Business Assets|Company Total Assets NAYA (NAYA Biosciences Inc.)|AAPGV - Cumulative Company Assets